NCT04377659: A reported trial by Memorial Sloan Kettering Cancer Center
This trial has reported on time, in line with the regulations.
Full data
Full entry on ClinicalTrials.gov | NCT04377659 |
---|---|
Title | A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection |
Results Status | Reported |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | May 1, 2020 |
Completion date | Oct. 28, 2022 |
Required reporting date | Oct. 28, 2023, midnight |
Actual reporting date | May 9, 2023 |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |